0001562180-21-005318.txt : 20210813 0001562180-21-005318.hdr.sgml : 20210813 20210813204408 ACCESSION NUMBER: 0001562180-21-005318 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210806 FILED AS OF DATE: 20210813 DATE AS OF CHANGE: 20210813 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Clark George C. CENTRAL INDEX KEY: 0001878290 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38080 FILM NUMBER: 211174073 MAIL ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Biohaven Pharmaceutical Holding Co Ltd. CENTRAL INDEX KEY: 0001689813 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 203-404-0410 MAIL ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 3 1 primarydocument.xml PRIMARY DOCUMENT X0206 3 2021-08-06 0 0001689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN 0001878290 Clark George C. C/O BIOHAVEN PHARMACEUTICALS, INC. 215 CHURCH STREET NEW HAVEN CT 06510 false true false false VP, Chief Accounting Officer Common Shares 5558.00 D Employee Stock Option (right to buy) 71.44 2031-05-06 Common Shares 10000.00 D Employee Stock Option (right to buy) 83.38 2031-01-06 Common Shares 7000.00 D Employee Stock Option (right to buy) 53.76 2029-12-05 Common Shares 8250.00 D Employee Stock Option (right to buy) 32.42 2028-11-20 Common Shares 6710.00 D Employee Stock Option (right to buy) 30.32 2028-03-11 Common Shares 1250.00 D Restricted Share Unit Award Common Shares 20000.00 D Restricted Share Unit Award Common Shares 2625.00 D Restricted Share Unit Award Common Shares 2000.00 D This balance includes 700 shares and 288 shares that were acquired through the Biohaven Employee Share Purchase Plan on November 30, 2020 and May 31, 2021, respectively, and 200 shares held in an individual retirement account. The reporting person was granted 3,500 restricted share units on January 6, 2021, vesting in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date. The reporting person was granted 4,000 restricted share units on January 8, 2020, vesting in four equal installments on January 8, 2020, 2021, 2022 and 2023, subject to the reporting person's continued service with the Issuer at each vesting date. The shares underlying this option became exercisable as to 2,500 of these shares on May 7, 2021, with the remainder vesting in 3 equal installments on May 7, 2022, 2023, and 2024, subject to the reporting person's continuing service as of each applicable vesting date. The shares underlying this option became exercisable as to 1,750 of these shares on January 6, 2021, with the remainder vesting in 3 equal installments on January 6, 2022, 2023, and 2024, subject to the reporting person's continuing service as of each applicable vesting date. The shares underlying this option became exercisable as to 3,750 of these shares on and prior to December 5, 2020, with the remainder vesting in 2 equal installments on December 5, 2021, and 2022, subject to the reporting person's continuing service as of each applicable vesting date. The shares underlying this option became exercisable as to 960 of these shares on and prior to November 20, 2020, with the remainder vesting in 2 equal installments on November 20, 2021, and 2022, subject to the reporting person's continuing service as of each applicable vesting date. The shares underlying this option will vest on March 12, 2022, subject to the reporting person's continuing service as of each applicable vesting date. Each restricted share unit represents the contingent right to receive one common share of the Issuer. The reporting person was granted 20,000 restricted share units on May 7, 2021, vesting in four equal installments on May 7, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date. Not applicable. Exhibit List: Exhibit 24: Power of attorney /s/ George C. Clark 2021-08-13 EX-24 2 gclarkpoa.txt POA POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Vlad Coric, James Engelhart and Douglas Gray, or either of them signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") any documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC; (2) execute for and on behalf of the undersigned Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by Biohaven Pharmaceutical Holding Company Ltd., unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 13th day of August, 2021. /s/ George C. Clark Signature George C. Clark Print Name